US-headquartered global pharmaceutical company with commercial and capability-center operations in India
lilly.comFounded
1876
Headquarters
Indianapolis, Indiana, USA
Industry
Pharmaceuticals
Employees
About 50,000 (2025)
Revenue (FY2025)
US$65.18 billion
Market Cap
Over US$1 trillion
Listed on
NYSE: LLYCEO
David A. Ricks (Chair & CEO)
Legal name
Eli Lilly and Company
Eli Lilly and Company is a US multinational pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. It trades on the New York Stock Exchange as LLY and employs about 50,000 people. The company reported revenue of US$65.18 billion for 2025 and became the first healthcare company to reach a trillion-dollar market capitalization in November 2025.
The company is led by David A. Ricks, who's been Chair and Chief Executive Officer since 2016. Lucas Montarce, a two-decade Lilly veteran, was appointed Executive Vice President and Chief Financial Officer in September 2024. Lilly has offices in 18 countries and sells its medicines in roughly 125 countries.
In India, Lilly runs two entities. Eli Lilly and Company (India) Private Limited, the commercial arm, is based in Gurgaon, Haryana. Eli Lilly Services India Private Limited, a capability center at Embassy Tech Village in Bengaluru, reported revenue of about Rs 1,617.3 crore in FY2025 with roughly 2,677 employees.
Chair and Chief Executive Officer
Executive Vice President and Chief Financial Officer
Managing Director, Eli Lilly Services India Private Limited (Bengaluru)
Director, Eli Lilly Services India Private Limited (Bengaluru)
Interview experience
8/10 (Positive)
Interview difficulty
Medium
Interview process length
About a week
Practice real questions and get instant feedback before the real thing.
Q: How would you describe the pharmaceutical market in (location)?
A: Show that you've done local homework. Talk through the main therapy areas, key hospital and clinic accounts, competitor presence, and any access or reimbursement quirks in that territory.
Q: Tell me about a time where you had to sell something that wasn't selling well, what did you do?
A: Use a STAR structure. Describe the underperforming product, the root cause you diagnosed, the specific plan you ran, and the measurable outcome.
Q: Describe how you would prepare for a sales call.
A: Walk through pre-call planning: research the account and prescriber, set a clear objective, tailor your message and materials, anticipate objections, and define the next step you want to close on.
Q: Have you ever been put on a performance improvement plan? What was the outcome?
A: Answer honestly. If yes, own it, explain what you changed, and share the result. If no, redirect to a time you took direct feedback and improved fast.
Practice real questions and get instant feedback before the real thing.
Self-reported average
₹22,46,549/year
7 Salaries submitted
Self-reported average
₹21,14,875/year
13 Salaries submitted
Self-reported average
₹18,02,159/year
5 Salaries submitted
Self-reported average
₹17,32,368/year
13 Salaries submitted
Self-reported average
₹15,86,425/year
5 Salaries submitted
Self-reported average
₹15,58,416/year
5 Salaries submitted
Compare offers, benchmark your role, and negotiate with confidence.
Bengaluru East, Karnataka, India • Full-time
Bengaluru East, Karnataka, India • Full-time
Bengaluru East, Karnataka, India • Full-time
Bengaluru East, Karnataka, India • Full-time
Greater Hyderabad Area, India • Full-time
Greater Hyderabad Area, India • Full-time
Tailor your resume to each Eli Lilly role in minutes.
May 7, 2026
Mounjaro overtakes Keytruda as the world's best-selling drug
Lilly's tirzepatide drug Mounjaro generated $8.7 billion in Q1 2026, passing Merck's Keytruda at $7.9 billion to become the world's top-selling medication. Combined with Zepbound, tirzepatide brought in $36.5 billion in 2025.
#Mounjaro #pharma #blockbuster
View postMay 1, 2026
Lilly lifts 2026 revenue guidance after Q1 revenue jumps 56% to $19.8 billion
Eli Lilly reported Q1 2026 worldwide revenue of $19.8 billion, up 56% year over year, and raised full-year 2026 guidance to $82 billion to $85 billion. Growth was driven by Mounjaro at $8.7 billion and Zepbound at $4.2 billion.
#earnings #GLP1 #EliLilly
View postDecember 26, 2025
Mounjaro becomes India's top-selling drug by value as obesity race heats up
Mounjaro became India's top-selling therapy by value in October 2025, with sales doubling within months of its March launch and ahead of Novo Nordisk's Wegovy. Analysts project India's obesity drug market could pass $1 billion within two years.
#IndiaPharma #obesity #Mounjaro
View postAugust 5, 2025
Lilly inaugurates second India capability centre in Hyderabad for AI and digital work
Eli Lilly opened a 220,000 sq ft global capability centre in Gachibowli, Hyderabad, its second in India after Bengaluru. It onboarded 100 professionals with plans to scale to 1,500, focused on AI, data science, automation, and cloud engineering.
#hiring #GCC #India
View postMarch 21, 2025
Lilly launches Mounjaro in India for obesity and type 2 diabetes
Lilly India launched Mounjaro (tirzepatide), a once-weekly GIP/GLP-1 injection, after CDSCO approval for chronic weight management and glycemic control. Lilly India president Winselow Tucker cited the rising dual burden of obesity and type 2 diabetes in India.
#launch #India #tirzepatide
View postEli Lilly and Company is headquartered in Indianapolis, Indiana, USA. In India, it operates through entities in Gurgaon, Bengaluru, and Hyderabad.
